替妥木单抗在长病程甲状腺眼病及再治疗中的疗效、安全性与持久性:OPTIC-X研究
OPTIC-X是在OPTIC试验后开展开放的替妥木单抗治疗与再治疗研究,纳入37例既往安慰剂和14例既往替妥木单抗患者。既往安慰剂患者中89.2%成为眼球突出应答者(平均下降3.5±1.7 mm),疗效与OPTIC相当;再治疗患者中初始应答不足或复发者也可获益,未发现新安全性信号。
要点
- 长病程TED患者对替妥木单抗的应答与早期治疗者相似。
- 既往安慰剂患者经替妥木单抗治疗,89.2%成为眼球突出应答者。
- 初始应答不足或复发患者可从再治疗中获益,未发现新安全性信号。
核心结论
- 替妥木单抗在长病程甲状腺眼病患者中应答与早期治疗者相似。
- 初始应答不足或复发的患者可能从额外替妥木单抗治疗中获益。
- 未发现新的安全性风险,但需继续上市后药物警戒。
研究设计与样本
- OPTIC-X是继安慰剂对照OPTIC试验后的开放标签扩展研究,评估替妥木单抗治疗与再治疗。
- 纳入OPTIC中既往接受安慰剂(n=37)或替妥木单抗(n=14)的患者。
- 无应答或复发者接受8次输注、共24周。
主要发现
- 应答者中第48周随访时眼球突出、CAS 0或1、复视应答分别维持于29/32(90.6%)、20/21(95.2%)、12/14(85.7%)。
- 5例OPTIC替妥木单抗无应答者再治疗,2例应答,1例眼球突出较OPTIC基线下降1.5 mm,2例提前终止。
- 8例OPTIC替妥木单抗应答后复发者再治疗,5例(62.5%)应答,平均眼球突出较OPTIC-X基线下降1.9±1.2 mm、较OPTIC基线下降3.3±0.7 mm。
- 未发现新安全性信号;报告轻度听力损害,首次治疗期间4例事件,再治疗后2例事件复现。
关键数值与推荐
- 眼球突出应答、CAS 0或1、复视应答为主要结局指标。
- 复发定义为眼球突出增加≥2 mm和/或CAS增加≥2分。
- 再治疗方案为24周内8次输注。
临床怎么用
- 长病程甲状腺眼病患者仍可考虑替妥木单抗治疗。
- 初始应答不足或复发患者可评估再治疗获益。
- 治疗期间关注听力损害等安全性事件。
局限性
- 开放标签扩展研究,非随机对照。
- 样本量较小,部分亚组例数有限。
- 需持续上市后药物警戒评估长期安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate teprotumumab safety/efficacy in patients with thyroid eye disease (TED) who were nonresponsive or who experienced a disease flare. DESIGN: The Treatment of Graves' Orbitopathy to Reduce Proptosis with Teprotumumab Infusions in an Open-Label Clinical Extension Study (OPTIC-X) is a teprotumumab treatment and re-treatment trial following the placebo-controlled teprotumumab Phase 3 Treatment of Graves' Orbitopathy (Thyroid Eye Disease) to Reduce Proptosis with Teprotumumab Infusions in a Randomized, Placebo-Controlled, Clinical Study (OPTIC) trial. PARTICIPANTS: Patients who previously received placebo (n = 37) or teprotumumab (n = 14) in OPTIC. METHODS: OPTIC nonresponders or those who flared (≥2-mm increase in proptosis, ≥2-point increase in clinical activity score [CAS], or both) during follow-up were treated for the first time (previous placebo patients) or re-treated with teprotumumab in OPTIC-X with 8 infusions over 24 weeks. MAIN OUTCOME MEASURES: Proptosis response and safety. Secondary outcomes included proptosis, CAS, subjective diplopia, and quality-of-life. RESULTS: Thirty-three of 37 placebo-treated OPTIC patients (89.2%) became proptosis responders (mean ± standard deviation, -3.5 ± 1.7 mm) when treated with teprotumumab in OPTIC-X. The responses were equivalent to the OPTIC study. In these responders, proptosis, CAS of 0 or 1, and diplopia responses were maintained in 29 of 32 patients (90.6%), 20 of 21 patients (95.2%), and 12 of 14 patients (85.7%), respectively, at follow-up week 48. The median TED duration was 12.9 months versus 6.3 months in those treated with teprotumumab in the OPTIC study. Of the 5 OPTIC teprotumumab nonresponders re-treated in OPTIC-X, 2 responded, 1 showed a proptosis reduction of 1.5 mm from OPTIC baseline, and 2 discontinued treatment early. Of the OPTIC teprotumumab responders who experienced flare, 5 of 8 patients (62.5%) responded when re-treated (mean proptosis reduction, 1.9 ± 1.2 mm from OPTIC-X baseline and 3.3 ± 0.7 mm from OPTIC baseline). Compared with published double-masked trials and their integrated follow-up, no new safety signals were identified. Mild hearing impairment was reported; 4 events occurred during the first course of treatment, and 2 events reoccurred after re-treatment. CONCLUSIONS: Patients with TED of longer disease duration responded similarly to those treated earlier in the disease course. Patients with an insufficient initial response or flare may benefit from additional teprotumumab therapy. No new safety risk was identified; however additional postmarketing pharmacovigilance is ongoing.
引用
- Douglas RS, Kahaly GJ, Ugradar S, et al. Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment: OPTIC-X Study. Ophthalmology. 2021. PMID: 34688699. doi:10.1016/j.ophtha.2021.10.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。